A multidisciplinary team of Cornell researchers is collaborating to elevate the value of home care workers while improving their working conditions and patient outcomes.
As the pandemic pomp and COVID circumstances dissipate, Cornell’s McGovern Center and Praxis Center incubators graduated five startups, putting them on the road to success.
A study suggests boosting “naturally-produced” antibodies in mothers may enhance infants’ immunity against bacterial pathogens that cause infectious gastrointestinal diseases.
The annual event showcased the wide range of cancer research taking place across Cornell colleges and campuses, and allowed faculty and students to identify potential areas for collaboration.
A class of proteins, known as TMEM16 scramblases, permit rearrangement of lipids in the cell membrane chiefly by thinning the membrane, according to a new model by Weill Cornell Medicine investigators.
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, according to a preclinical study by investigators at Weill Cornell Medicine.
Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth.
The Weill Cornell Medicine research takes a step toward precision medicine for a type of cancer that disproportionately affects people with African ancestry, an underserved population.
Cornell startup Antithesis Foods and Bactana were awarded NSF small-business grants, as Guard Medical raises $11 million in Series B investments and C2i launches a disease test in Europe.
